In brief
- The DEA proposes including five hallucinogenic tryptamines in Schedule I of the US Controlled Substances Act.
- The filing is based on 518 cumulative police seizures and 65 cases reported to poison control centers between 2003 and 2021.
- No single-substance deaths were reported in any of these cases, according to the document itself. The public comment period is open until October 23.
On September 23, 2026, the US Drug Enforcement Administration (DEA) published a proposal in the Federal Register to include five lesser-known hallucinogenic tryptamines in Schedule I, the most restrictive category of the federal Controlled Substances Act. The substances are 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT—compounds chemically related to DMT and psilocin.
What the DEA is proposing
The document (docket DEA-2026-1585) is a notice of proposed rulemaking, not a final rule: it opens a public comment period until October 23, 2026, and allows for the possibility of requesting a hearing. The agency argues that the five substances have a “high potential for abuse” and lack a “currently accepted medical use” in the United States, the two legal criteria required to justify Schedule I status.
Data cited in the filing
According to the DEA, US law enforcement has recorded a cumulative total of 518 encounters with these five tryptamines across various states and the District of Columbia through its NFLIS-Drug system. Meanwhile, a 2026 review by the Department of Health and Human Services (HHS), based on the national NPDS poison control database, documents 65 exposure cases between January 1, 2003, and December 31, 2021: more than 61% involved a single substance, 84% were classified as “abuse,” and over 89% were reported by healthcare facilities. The file notes a single death, in 2004, associated with 5-MeO-AMT, in which the toxicology report also detected alcohol and the antidepressant bupropion; in other words, it was not a single-substance case. A non-lethal intoxication in an adolescent in 2005 is also documented following the consumption of a combination of 5-MeO-MiPT and harmaline.
Implications
This is a notice of proposed rulemaking, not an active ban. The underlying recommendation was sent by the HHS to the DEA in a letter dated April 2, 2026, and the DEA claims to have completed its own eight-factor analysis in August 2021, updated in May 2026. The health data supporting the file is sparse: 65 cases in nearly two decades, which the text itself describes as sporadic and mostly involving mild or moderate consequences, although the HHS warns that its toxicology system only captures a small fraction of what occurs outside of hospitals.
If the rule moves forward, research involving these molecules will require the registrations and controls of Schedule I; the DEA assumes the impact will be minimal because those working with them are likely already registered for other controlled substances. For those who use them, the file provides useful information: the document admits there is barely any data on their potential for dependence, and nearly four out of every ten reported cases also involved other substances, so combinations deserve as much attention as the dosage. More context is available in the psychedelic science and therapy section of Psiconáutica.
Source
- Drug Enforcement Administration. Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I. US Federal Register, September 23, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
